This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: P22.9 (Respiratory distress of newborn, unspecified) | Special Copayment Reduction: V142 (severe intractable disease, 5 years) |
| B. Synonyms | No separate synonyms (unspecified code) |
| C. Adult onset | None — limited to the neonatal period (within 28 days of birth). |
| 1. History | P22.9 is a residual code in the ICD classification for cases in which the cause of neonatal respiratory distress is uncertain or not recorded; it is trending toward replacement by accurate codes as diagnostic capability improves. |
| 2. Causes | Neonatal respiratory distress in general with undetermined diagnosis; cases in which the cause is difficult to identify at initial evaluation. |
| 3. Genetics | Varies with cause; rare surfactant metabolism disorder gene variants possible. |
| 4. General epidemiology | Incidence of the code itself is difficult to estimate; respiratory problems are the principal diagnosis in about 15–20% of neonatal admissions. |
| 5. Pathophysiology | Cause unidentified; includes the full range of possible mechanisms (surfactant deficiency, delayed lung fluid clearance, pulmonary vascular abnormalities, etc.). |
| 6. Symptoms | Tachypnea, chest retractions, grunting, cyanosis; onset immediately after birth is typical. |
| 7. Signs | Chest radiograph, arterial blood gas analysis; echocardiography; tests to differentiate causes are carried out. |
| 8. Screening | SpO₂ monitoring; early evaluation of high-risk newborns. |
| 9. Diagnosis | Stepwise identification of cause; chest radiograph, blood gas, echocardiography, infection workup. |
| 10. Treatment | Supplemental oxygen, CPAP; cause-specific treatment once the cause is identified; empirical antibiotics. |
| 11. Prognosis | Varies with cause; prompt evaluation and treatment determine prognosis. |
| 12. Prevention | Optimization of prenatal care; preparation for high-risk delivery; preparation for neonatal resuscitation. |
| 13. References | Bancalari E et al. and 9 other references |
ICD-10 code P22.9 is a residual code in the 'unspecified' category of the neonatal respiratory distress classification system. This code is used when a newborn shows respiratory distress symptoms but it is difficult to classify as P22.0 (RDS due to surfactant deficiency) or P22.8 (other specified causes), or when the cause has not yet been identified at the initial evaluation stage. In actual clinical practice, it is often used as a temporary code while the cause is being determined, or remains in discharge or transfer records without a specific diagnosis having been made in resource-limited settings.
Historically, awareness of neonatal respiratory distress has existed since the early 20th century, but differentiation by cause came with the development of neonatology in the 1950s–70s. Before the nationwide spread of NICUs in the 1970s–80s, many newborns with respiratory distress died or recovered without their cause being specifically classified, and such cases would have been classified under the 'unspecified' code corresponding to P22.9.
At present, use of the P22.9 code is gradually declining in neonatal intensive care settings in developed countries. This is because advances in diagnostic tools such as lung ultrasound, echocardiography, and molecular diagnostic technology have made it possible to identify the cause of respiratory distress within a few hours of birth. On the other hand, in resource-limited regions or local clinic-level medical institutions, the P22.9 code can still account for a high proportion.
As we enter the ICD-11 era, the classification of neonatal respiratory distress has become more detailed, and specific cause-based coding is emphasized in healthcare quality assessment and epidemiologic research. The principle is to use P22.9 as a temporary code and change it to a specific code once the final diagnosis is confirmed.
Because P22.9 by definition covers neonatal respiratory distress with no specified cause, the range of potential causes is very wide. Situations classified as P22.9 in clinical practice can be divided broadly into two.
This is when the cause of respiratory distress is unclear immediately after birth or at the initial evaluation stage. It is used temporarily when chest radiograph findings are nonspecific, when multiple causes coexist, or while diagnostic tests are in progress. Examples include cases where the radiographic findings of GBS pneumonia and RDS are similar, or where mild respiratory distress improved in a short time and no specific cause workup was done.
Rare causes that do not correspond to a specific disease of P22.0 or P22.8 can also be classified as P22.9. These include respiratory failure due to congenital neuromuscular disease (congenital myotonic dystrophy, spinal muscular atrophy type 1), congenital central hypoventilation syndrome (CCHS), rare hereditary surfactant metabolism disorders (SP-B, SP-C, ABCA3 deficiency; very rare, and confirmation takes time even after treatment), respiratory distress due to upper airway malformations (choanal atresia, Pierre Robin sequence, laryngomalacia), secondary respiratory distress due to congenital heart malformations, and neonatal seizures accompanied by decreased oxygen saturation.
In idiopathic PPHN, where pulmonary artery pressure is elevated without a clear underlying cause, cases may initially be classified as P22.9 and later reclassified as PPHN based on echocardiography results.
Initial classification can be unclear when apnea of prematurity appears together with respiratory distress, or when mild RDS presents mainly as apnea without surfactant deficiency.
In neonatal respiratory distress classified as P22.9, the cause has not been identified, so the genetic background is difficult to know in advance. However, several rare genetic diseases may later be identified as the cause of P22.9.
Congenital central hypoventilation syndrome (CCHS, Ondine's curse) is an autosomal dominant disease caused by the PHOX2B gene (polyalanine repeat expansion or missense variants) and presents in the neonatal or infant period as failure of respiratory control during sleep. When it presents in the neonatal period, it is initially classified as P22.9 and then confirmed by genetic testing.
Spinal muscular atrophy type 1 (SMA type I, Werdnig-Hoffmann disease) is an autosomal recessive disease caused by deletion of the SMN1 gene, presenting in the neonatal or early infant period with hypotonia and respiratory failure. SMA should be considered when differentiating neonatal respiratory distress in neonatal intensive care.
Congenital myotonic dystrophy (CDM) is a maternally inherited disease caused by CTG repeat expansion in the DMPK gene and can present in the neonatal period with severe hypotonia, respiratory failure, and dysphagia. Suspect it when the mother also has myotonic dystrophy symptoms.
Rare surfactant metabolism disorders (variants in SFTPB, SFTPC, ABCA3, NKX2-1 genes) can present as intractable neonatal respiratory distress with poor response to surfactant therapy; they are difficult to distinguish from RDS initially and are classified as P22.9 or P22.0, then confirmed by genetic testing.
It is difficult to determine the incidence of the P22.9 code itself accurately. Because this code is used in temporary or undetermined-diagnosis states, the frequency of code use varies greatly with a medical institution's diagnostic capability and coding practices.
Overall, neonatal respiratory problems are a leading cause of admission to neonatal intensive care units. Worldwide, respiratory problems are the principal diagnosis in about 15–20% of neonatal admissions. There are reports from developed countries that about 5–10% of newborns admitted to neonatal intensive care units are registered under the P22.9 code, but this varies greatly with institutional coding habits and systems.
In Korea, in National Health Insurance claims data, the number of claims filed under P22.9 is in some cases considerably higher than for P22.0, which may be because some medical institutions use the 'unspecified' code for convenience without identifying the specific cause. From the standpoint of improving quality of care, monitoring the appropriateness of P22.9 use and shifting to specific diagnostic coding are recommended.
Among rare causative diseases (CCHS, SMA, congenital myotonic dystrophy, etc.), those that can be classified as P22.9 in the neonatal period each have a very rare incidence of a few per million.
Because P22.9 is an unspecified code, it cannot be explained by a single pathophysiologic mechanism. The common physiologic mechanisms of neonatal respiratory distress are as follows.
Whatever the cause, the common final pathway is insufficient alveolar ventilation leading to hypoxemia and hypercapnia. Several mechanisms can cause this: surfactant deficiency (alveolar collapse), excess lung fluid (decreased lung compliance), airway obstruction (mechanical or functional), pulmonary vascular hypertension (decreased blood flow), and decreased function of the respiratory center or muscles.
Suppression of the respiratory center due to CCHS, oxygen deficiency during delivery, or drug effects (anesthetics, magnesium toxicity) leads to reduced neonatal respiratory effort. In this case the cause is a lack of respiratory drive rather than a problem of the lungs themselves.
In SMA, congenital myotonic dystrophy, congenital myopathy, and the like, weakness of the respiratory muscles (mainly the diaphragm) prevents generation of sufficient tidal volume. The chest wall moves, but it is difficult to sustain the work of breathing against airway resistance, so progressive respiratory failure occurs.
In choanal atresia, because newborns are obligate nasal breathers, complete upper airway obstruction causes immediate respiratory failure. In Pierre Robin sequence (micrognathia, glossoptosis, cleft palate), the tongue is displaced posteriorly and partially obstructs the airway.
The symptoms seen in P22.9 are the general pattern of neonatal respiratory distress, with common respiratory failure symptoms appearing regardless of the specific cause.
The basic symptoms are tachypnea (60 breaths per minute or more), chest retractions (intercostal, substernal, supraclavicular retractions), grunting (partial glottic closure during expiration), nasal flaring, and cyanosis (peripheral or central). In severe cases, apnea episodes, bradycardia, and hypotonia may accompany.
The timing and pattern of symptom onset differ somewhat by cause. In transient tachypnea of the newborn, tachypnea is the main symptom, other symptoms are mild, and improvement occurs within hours to days. With airway malformations, symptoms may worsen with crying or feeding. In neuromuscular disease, hypotonia (floppy infant) and difficulty sucking and swallowing accompany respiratory distress. In heart disease, cyanosis is prominent and a heart murmur may be present on auscultation.
When classified as P22.9, the cause is not clear from initial symptoms alone, so an approach of carefully evaluating the characteristics of the symptoms (timing of onset, oxygen responsiveness, accompanying symptoms, delivery history) and narrowing down possible causes is needed.
In newborns with P22.9, physical examination and initial tests are the first step in differentiating the cause.
On physical examination, evaluate the degree of respiratory effort (location and depth of retractions), auscultation findings (symmetry of breath sounds, heart murmurs, crackles), skin color (degree of cyanosis, jaundice, meconium staining), muscle tone (hypotonia suggests neuromuscular disease), and malformations (micrognathia, cleft palate, and other clues to upper airway malformation).
A pre-ductal (right wrist) versus post-ductal (foot) SpO₂ difference >3–5% suggests a right-to-left shunt through the ductus arteriosus, i.e., PPHN or a congenital heart malformation.
Chest radiograph is important for narrowing the cause by lung opacity pattern. Arterial blood gas analysis assesses the degree of hypoxemia and hypercapnia. Echocardiography is key for differentiating PPHN and congenital heart malformations. Complete blood count, CRP, and blood culture are needed to exclude infection. Blood glucose, electrolytes, and calcium tests must be included, since metabolic abnormalities in newborns can cause or worsen respiratory distress.
There is no specific test method to screen for P22.9 in advance, but a systematic evaluation protocol for newborns at risk of respiratory distress helps early diagnosis.
Pulse oximetry screening for congenital heart malformations, performed in all newborns within 24–48 hours after birth, is important for early detection of congenital heart disease hidden within P22.9. Measure SpO₂ in the right hand (pre-ductal) and lower limb (post-ductal); it is normal if both are ≥95% and the difference is ≤3%.
Preterm infants, infants of diabetic mothers, and infants born by cesarean section without labor are intensively observed for 2–6 hours after birth. When lung or airway malformations are suspected on prenatal ultrasound, specific evaluation begins immediately after birth.
When neuromuscular disease is suspected (maternal myotonic dystrophy, family history, decreased fetal movement), prepare a pediatric neurology consultation before delivery and perform neurologic evaluation immediately after birth.
Because P22.9 is a code used temporarily during the process of identifying the cause, the goal of diagnosis is to specify the cause and convert to a specific code.
Stage 1 evaluation (immediately after birth): physical examination, SpO₂ monitoring, chest radiograph (AP), arterial blood gas analysis, CBC + CRP, blood glucose, blood culture.
Stage 2 evaluation (if respiratory distress persists): echocardiography (assessment of PPHN and congenital heart malformations), pre-/post-ductal SpO₂ comparison, electrocardiogram, follow-up chest radiograph, serum electrolytes and calcium, procalcitonin.
Stage 3 evaluation (if cause remains unidentified): metabolic screening (possibility of metabolic disease not included in newborn screening), chest CT (detailed assessment of airway and lung malformations), bronchoscopy (direct observation of upper airway malformations), nerve conduction study and electromyography (neuromuscular disease), PHOX2B, SMN1, and DMPK genetic testing (CCHS, SMA, congenital myotonic dystrophy), surfactant protein gene panel (SFTPB, SFTPC, ABCA3).
In the diagnostic process, multidisciplinary consultation with related specialties such as pediatric pulmonology, pediatric cardiology, pediatric neurology, and pediatric genetics is often needed.
In P22.9, supportive symptomatic treatment is given until the cause is identified, and treatment is converted to cause-specific treatment after the cause is identified.
Initial supportive care: Supplemental oxygen (nasal cannula or oxygen hood), maintaining a target SpO₂ of 88–95% (preterm) or 95–99% (term). In some cases, CPAP (PEEP 5–8 cmH₂O) to prevent alveolar collapse. Maintenance of body temperature (hypothermia increases metabolic demand and worsens breathing), normalization of blood glucose, fluid supply.
In early-onset respiratory distress in which infection has not been excluded, start empirical antibiotics (ampicillin + gentamicin) immediately after obtaining blood cultures, and stop them if cultures are negative at 48–72 hours and infection markers are normal.
After the cause is identified, treatment is converted to that suited to each cause: iNO for PPHN, surgery or intervention for congenital heart malformations, pediatric surgical or otolaryngologic surgery for airway malformations, planning of long-term respiratory support (mechanical ventilation, tracheostomy) for neuromuscular disease, and repeated surfactant administration and consideration of lung transplantation for rare surfactant disorders.
The prognosis of P22.9 varies greatly with the causative disease ultimately identified. When the cause is common neonatal respiratory distress (TTN, mild RDS, etc.), the prognosis is good. However, when the cause is PPHN, congenital heart malformation, congenital anomaly, neuromuscular disease, or the like, the prognosis can be poor.
CCHS requires lifelong nocturnal or full-time mechanical ventilation and is accompanied by autonomic dysfunction (cardiac arrhythmia, thermoregulation disorder, association with Hirschsprung disease, etc.). SMA type 1 has a very high mortality within 2 years of life, but since the introduction of new therapies such as nusinersen and onasemnogene abeparvovec, survival and functional prognosis have improved markedly. Rare surfactant metabolism disorders (SP-B deficiency, etc.) do not respond to surfactant therapy and have high mortality without lung transplantation.
A newborn registered under P22.9 should have the code changed to the accurate code after the cause is identified, and a long-term follow-up plan according to the cause should be established.
Prevention of P22.9 consists of prevention strategies according to individual causes and optimization of overall neonatal health care. Prenatal care includes regular prenatal ultrasound (early detection of lung, airway, and heart malformations), infection screening (GBS, rubella, CMV, etc.), management of gestational hypertension and diabetes, and minimizing drug exposure (especially drugs with a risk of neonatal respiratory depression). Prenatal genetic counseling and family history assessment are also important.
At delivery, ensure immediate participation of pediatric and neonatal physicians in all high-risk deliveries (preterm birth, fetal abnormality, maternal complications, etc.), and prepare neonatal resuscitation equipment and personnel. Apgar score assessment and respiratory status monitoring immediately after birth are performed in a standardized manner.
Newborn screening allows early detection of congenital metabolic diseases and some genetic diseases, and treatment can be started before symptom onset. For SMA, in countries where SMN1 gene testing is included in newborn screening, presymptomatic treatment can dramatically improve prognosis.